No Data
JMP Securities Reiterates Market Outperform on LAVA Therapeutics, Maintains $6 Price Target
Jefferies Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
Jefferies analyst Roger Song maintains $LAVA Therapeutics(LVTX.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 30.1% and a
LAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Bolster Buy Rating
Buy Rating Affirmed: LAVA Therapeutics' Financial Stability and Promising Clinical Pipeline
LAVA Therapeutics Faces Financial Hurdles
Express News | LAVA Therapeutics NV- Qtrly Shr Loss $0.31